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Cell damagePathogen inactivation (PI) for platelet concentrates (PC) is a fairly recent development in transfusion medicine
that is intended to decrease infectious disease transmission from the donor to the receiving patient. Effective in-
activation of viruses, bacteria and eukaryotic parasites adds a layer of safety, protecting the blood supply against
customary and emerging pathogens. Three PImethods have beendescribed for platelets. These are based on pho-
tochemical damage of nucleic acids which prevents replication of most infectious pathogens and contaminating
donor leukocytes. Because platelets do not replicate, the collateral damage to platelet function is considered low
to non-existing. This is disputable however because photochemistry is not speciﬁc for nucleic acids and signiﬁ-
cantly affects platelet biomolecules as well. The impact of these biomolecular changes on platelet function and
hemostasis is not well understood, but is increasingly being studied. The results of these studies can help explain
current and future clinical observations with PI platelets, including the impact on transfusion yield and bleeding.
This review summarizes the biomolecular effects of PI treatment on platelets. We conclude that despite a com-
parable principle of photochemical inactivation, all three methods affect platelets in different ways. This knowl-
edge can help blood banks and transfusion specialists to guide their choicewhen considering the implementation
or clinical use of PI treated platelets.sesteenweg 413, 9000 Gent,
.
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prevent transmission of pathogens in plasma. The past years, similar
technologies have been developed for platelet concentrates (PC) andrecently were adopted in routine use in several countries worldwide.
These technologies have been shown to inactivate bacteria, viruses
and parasites that were experimentally added to PC in laboratory set-
tings. The inactivation efﬁciency is variable and depends on the PI
method, the type and number of contaminating pathogens [1-4]. The
supplementary inhibition of donor leukocytes could render gamma irra-
diation for prevention of transfusion associated Graft-versus-Host-creativecommons.org/licenses/by-nc-nd/4.0/).
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transmission of pathogens from the donor to the thrombocytopenic pa-
tient during PC transfusion. Patients that require platelet transfusion
sometimes are immunocompromised to varying degrees and therefore
the inactivation of both pathogens and donor leukocytes offers a great
potential for reducing adverse events related to disease transmission
[5]. Current PI technologies target the replication machinery of patho-
gens by directly damaging or modifying the organism's nucleic acids
(DNA and RNA) with photochemical modiﬁcation.
Our Belgian (EU) national parliament was the ﬁrst in the world to
pass a bill in 2009 that mandates nationwide PI for all PC distributed
to hospitals for transfusion. The law came into force in 2013 following
additional recommendations to the blood establishments. These in-
cluded a minimal platelet dose criterion of 3.0 X 1011 per PC and a lim-
itation of the shelf life from seven toﬁve days following concerns over PI
platelet efﬁcacy after storage. The implementation in our blood service
was furthermore hampered by risks of aseptic breaches, arising from
perforations of PI bag systems.
For platelets, three methods have been developed of which two are
currently commercially available. The ﬁrst available technology (AS-
PCT) uses a proprietary psoralen derivative called amotosalen as a pho-
tosensitizer in combinationwith ultraviolet (UV) A light andwas devel-
oped by Cerus Corporation (Concord, CA) [6, 7]. It is used in more than
40 countries including ours. The second technology uses riboﬂavin (RF-
PRT) in combination with a broad wavelength spectrum of UV light
(TerumoBCT, Lakewood, CO) [8]. It is used in over 15 countries including
the CzechRepublic, Poland and Egypt. The latest technology (UVC)does
not include a photosensitizer but exploits the inherent high energy of
narrow band shortwave UV C light (Macopharma, Tourcoing, France)
[9]. This technology is not yet in routine use.
The in vitro quality of PC treated with each of these PI methods has
been investigated by several groups over the past years. Most data are
available for AS-PCT and the least for UV C, in order of their respective
chronologic tracks. In all cases in vitro platelet studies indicate anything
from low to normal platelet quality depending on the study design, the
projected acceptance criteria and the experimental approach. In ad-
dition, primary product type and product composition often differ by
country or by blood institution. Factors like plasma content, white
and red cell contamination, total product volume, bag plastics, and
platelet content all inﬂuence the outcome of longitudinal quality
control studies and therefore represent important variables. The re-
cent clinical study by Garban et al [10] conﬁrmed this by showing
the importance of plasma as a contributing factor when comparing
AS-PCT treated PC with untreated control PC in patients with hema-
tologic malignancies.
Platelets are small anucleate and discoid cells. They are produced by
megakaryocyteswhich reside in bonemarrow [11] and lung [12]. About
1011 fresh platelets are released daily in a healthy circulation. A normal
platelet concentration is between 1.5 and 4.5 X108 cells permL of blood.
During hemostasis, platelets initially adhere to injured blood vessels
through interactions of the platelet speciﬁc GPIbα-IX-V receptors with
von Willebrand factor. Subsequent ﬁrm arrest of platelets is mostly
through integrin interactions with the denuded subendothelial matrix
[13]. During this process platelets become activated, change morphol-
ogy and recruit additional platelets as well as coagulation factors to
eventually stop bleeding through an insoluble platelet and ﬁbrin plug
at the injured site. Hemostasis signiﬁcantly slows down in the absence
of platelets, leading to potentially fatal hemorrhage if not corrected by
a platelet transfusion. A typical transfusion delivers 3.0 X 1011 stored
donor platelets to the thrombocytopenic patient. Storage is short (4–7
days) because even in optimal conditions a gradual decline in platelet
function is found. This storage lesion is a complex biochemical process
which is not related to intrinsic apoptosis [14].
Excellent reviews are available in literature describing our current
understanding of platelet storage lesion [15] as well as several aspects
of the available PI methods [16-18]. The reader is referred to these forPlease cite this article as: Feys HB, et al, Biomolecular Consequences of Plat
doi.org/10.1016/j.tmrv.2018.06.002details on PImethodology, inactivation potency and clinical use. This re-
view will however focus on the biochemical effects of PI and present
current understanding of the impact that PI can have on platelets.
Amotosalen and UV A Light
Amotosalen (or S59) is a furanocoumarin that can intercalate in he-
lical regions of DNA and RNA [19]. The AS-PCT process uses approxi-
mately 150 μM amotosalen with 3.9 J/cm2 of UV A light. Upon
photoexcitation of amotosalen in the vicinity of nucleic acids, covalent
monoadducts can be formed with thymidine bases (Figure) [20].
These chemical modiﬁcations efﬁciently inhibit subsequent DNA or
RNA (reverse) transcription, thereby preventing replication of many
pathogens and leukocytes [21]. Because the functional target is biologi-
cal proliferation and because platelets do not replicate, the technology
seemingly affects dividing life forms only, and not platelets. However,
several lines of research including ours show that platelets readily
react with photoexcited amotosalen during AS-PCT and this is indepen-
dent of pathogen contamination.
Modiﬁcations of Nucleic Acids
Although platelets may not replicate [22], they do carry signiﬁcant
amounts of nucleic acid in diverse RNA forms, including short mRNAs
andmiRNA but also long non-coding RNA and ribosomal RNA [23]. Con-
sequently, amotosalen chemistry with platelet RNA will inevitably take
place upon photoexcitation and modify the platelet transcriptome. This
was conﬁrmed by RNAseq based genome-wide differential expression
analysis, showing that 147 genes become deregulated by ≥2-fold fol-
lowing AS-PCT [24]. Functional clustering analysis of these genes sug-
gested signiﬁcant changes in AS-PCT platelet membrane function,
transport, metabolism and structure compared to untreated control.
Some uncertainty still exists around platelet RNA function [25, 26], but
biochemical evidence for protein translation [27, 28], pre-mRNA splic-
ing [29], processing of miRNA precursors [30], functional miRNA [31]
suggests signiﬁcant roles for RNA beyond being a mere remnant from
thrombopoiesis [32]. For instance, a decrease in the mRNA levels for
the pro-survival protein Bcl-XL suggests that platelets treated with AS-
PCT may turn to apoptosis quicker than untreated platelets [33].
The AS-PCT method also modiﬁes platelet mitochondrial DNA
(mtDNA).Mitochondria in platelets logically deliver energy equivalents,
but also play a role in hemostasis and necrosis [34, 35]. In addition, the
release ofmtDNA during storage has recently been linked to transfusion
adverse events [36, 37]. Approximately 4.0 ± 1.2 (n = 6) amotosalen
adducts per 1000 base pairs of mtDNA are found in AS-PCT treated
platelets. This is less than the 12 ± 3.0 adducts per 1000 base pairs
found in nuclear DNA, but still sufﬁcient to prevent mtDNA replication
[38]. The mtDNA modiﬁcations in platelets are currently investigated
as a form of quality control for AS-PCT treatment using real-time poly-
merase chain reaction [39]. The biomolecular changes in mtDNA do
not lead to mitochondrial depolarization [40, 41] implying that AS-PCT
does not alter the pH gradient across the mitochondrial membrane. It
therefore remains to be demonstrated that the changes to the platelet
transcriptome (RNA) and platelet mtDNA account for downstream ef-
fects like functional decline [42, 43] or reduced survival after transfusion
[17].
Modiﬁcations to the Platelet Membrane Leading to Signal Transduction
Defects
Our initial study of AS-PCT platelets in additive solution was in
microﬂuidic ﬂow chambers with real-time ﬂuorescence microscopy
[44]. The data showed signiﬁcantly reduced platelet thrombus forma-
tion kinetics to immobilized collagen for AS-PCT treated platelets com-
pared to paired untreated controls [42]. This was an acute defect,
evident immediately after AS-PCT treatment which did not recoverelet Pathogen InactivationMethods, Transfus Med Rev (2018), https://
Figure. The impact of three PI methods for platelets. Current PI methods are amotosalen photochemical treatment (AS-PCT) or the Intercept method (orange); riboﬂavin pathogen
reduction technology (RF-PRT) or the Mirasol method (green) and ultraviolet C (UV-C) or the Theraﬂex UVC method (purple). The targeted damage to (pathogen) proliferation is
summarized on a common DNA triple helix to the left. The molecular structure of photosensitizers and UV light wavelengths are given in the arrows. To the right, speciﬁc
biomolecular consequences for platelets are depicted; AS-PCT damages nucleic acids like RNA and mitochondrial DNA by covalent modiﬁcation. Lipid molecules are also targeted by
AS-PCT leading to changes in membrane packing and subsequent defects in platelet signal transduction. RF-PRT modiﬁes proteins including labile proteins like FVIII by oxidative
mechanisms. Platelet metabolism increases leading to increased rates of lactic acid following RF-PRT. UV-C impacts integrin structure and increases in metabolism are also found.
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addition, activation of the ﬁbrinogen receptor integrinαIIbβ3 was signif-
icantly impaired when platelets were stimulated via the thrombin re-
ceptor, PAR1. In fact, the agonist dose needed to achieve a comparable
response to untreated controls was twofold [45]. These ﬁndings inevita-
bly becamepart of the inconsistent literature on AS-PCT platelet quality,
so we next questioned why AS-PCT platelets are less responsive to ago-
nist stimulation.
To this purpose, all major known signal transduction pathways in
platelets were interrogated. Signiﬁcant decreases were found only for
Akt phosphorylation, pointing to defective phosphatidylinositol-tris-ki-
nase (PI3K) signaling in AS-PCT treated platelets [45]. Surprisingly, the
enzyme product of PI3K, phosphatidylinositol(3,4,5)-tris-phosphate
(PIP3) was not decreased. This PIP3 inositide is generated in the inner
cell membrane leaﬂet in response to cell activation, providing a major
nucleation site for downstream signal transduction. Key effector mole-
cules Akt and Bruton's tyrosine kinase (Btk) become phosphorylated
at these sites, butmuch less in AS-PCT treated platelets. Signal transduc-
tion through the PI3K axis is important for platelet granule secretion,
platelet aggregation and thrombus formation [46-48]. Impaired Akt
and Btk phosphorylation but normal PIP3 levels implied inhibition of
Akt/Btk binding to PIP3 rather than a malfunctioning PI3K enzyme
reaction.
Because the PI3K axis requires normal membrane interactions and
because psoralens are known to biophysically partition to membranes
[49], we investigated platelet membrane composition next. Using
targeted lipidomics, amotosalen adducts were readily found in all clas-
ses of membrane phospholipids with unsaturated fatty acyl side chainsPlease cite this article as: Feys HB, et al, Biomolecular Consequences of Plat
doi.org/10.1016/j.tmrv.2018.06.002[45]. The latter is important because unsaturated carbon side chains
cause pivotal structural membrane features called lipid packing defects
(LPD). These are dynamic gaps in the hydrophilic sheet that tops each
bilayer leaﬂet [50]. The gaps accommodate protein-membrane interac-
tions [51]. Chemical modiﬁcation of unsaturated phospholipids with
amotosalen indeed caused fewer LPD, preventing the interaction of
model proteins like the amphipathic-lipid-packing-sensor motif
(ALPS) and α-synuclein with AS-PCT treated liposomes. Discerning be-
tween membrane-bound and cytoplasmic Akt allowed to subsequently
demonstrate that binding of Akt to the amotosalenmodiﬁedmembrane
indeedwas inhibited in the AS-PCT treated platelet [45]. These data pro-
vide a mechanistic explanation for why platelet activation by signaling
pathways that include the PI3K axis are impaired after AS-PCT treat-
ment (Figure). Whether the changes in membrane composition also
cause the increased clearance rates of transfused AS-PCT platelets
needs further investigation.
Our ﬁndings furthermore imply that amotosalen (photoproducts)
remains bound to AS-PCT treated platelets and are transfused. Indeed,
it is estimated that 4 mg of amotosalen remains in a standard PC after
AS-PCT [52], of which half is bound to platelets. These levels have not
been found to be toxic in animal studies and clinical trials in patients
[52-54]. Based on these and available lipidomics data [55], we estimate
that maximally 4% of all membrane lipids are in complex with
amotosalen. But, the photochemical reaction of amotosalen with lipids
is selective for phospholipids with unsaturations so the modiﬁed frac-
tion of that subspecies will be larger. The consequences are nonetheless
large enough to render the cytoplasmic membrane less accessible for
membrane binding kinases.elet Pathogen InactivationMethods, Transfus Med Rev (2018), https://
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Riboﬂavin is a water soluble essential vitamin (B2). The mole-
cule is therefore considered safe for injection, thereby avoiding
the cumbersome adsorption step required for AS-PCT to remove
photosensitizer. In RF-PRT practice, on average 50 μM of riboﬂavin
is added to a PC and illuminated with broad spectrum UV light
(280–400 nm) at a dose of 6.2 J/mL [56]. The delivered light energy
in this case is dependent on the exact product volume implying that
every PC is weighed before photo-treatment. The photochemical
pathogen inactivation of RF-PRT is governed by several possible
redox reactions. Guanine bases in DNA or RNA may accept electrons
directly from photosensitized riboﬂavin, but in the presence of dis-
solved molecular oxygen the reaction shifts towards substantive re-
active oxygen species (ROS) formation [57]. Oxygen species like
singlet oxygen, superoxide anion and hydroxyl radicals strongly
damage biomolecules, including DNA. These reaction products
then efﬁciently prevent replication and proliferation of many path-
ogens [58] and leukocytes.Modiﬁcations to proteins by reactive oxygen species
In a comparable study as for AS-PCT, microﬂuidic ﬂow chambers
with real-time ﬂuorescence microscopy were used to measure he-
mostasis of RF-PRT platelets in reconstituted blood perfused over
immobilized collagen. Similar to AS-PCT, the RF-PRT treatment sig-
niﬁcantly and immediately reduced platelet thrombus formation
compared to controls [42, 59]. In addition, platelet aggregation via
thrombin receptor activation was signiﬁcantly decreased. Premature
platelet degranulation was moreover increased. Aggregation defects
and premature degranulation were not observed in AS-PCT treated
platelets in our hands [42], but a direct comparison with paired RF-
PRT treated samples was never performed.
Although we were unable to dissect the biochemical conse-
quences of RF-PRT technology on platelets in detail, earlier data
from our team showed that superoxide anion is a dominant ROS
formed during RF-PRT of plasma [60] (Figure). This study followed
a comparative analysis of plasma PI methods that found signiﬁcantly
reduced activities for FVIII, ADAMTS13 and ﬁbrinogen in RF-PRT
treated plasma compared to AS-PCT and methylene blue photo-
treatment [61]. Proteins in RF-PRT plasma were signiﬁcantly
carbonylated, which is a toxic endpoint modiﬁcation of oxidative
damage in proteins. These ﬁndings were conﬁrmed in RF-PRT
treated platelets by Johnson and Marks [62]. Of note, by performing
RF-PRT in experimental conditions of hypoxia, the damage to labile
plasma proteins could be rescued [60] proving that oxidative dam-
age indeed underlies the functional decline of plasma treated with
RF-PRT. It is not clear if these hypoxic conditions which are useful
to safeguard plasma proteins, would equally safeguard platelet qual-
ity and retain sufﬁcient photochemical potential to kill pathogens at
the same time.
Indirect modiﬁcations to proteins following RF-PRT were also re-
ported multiple times. In particular, increased phosphorylation was
found for the cytoskeleton regulator VASP [63], the stress responsemol-
ecules p38MAPK [64], NF-κB and IκBα [62]. The changes to p38MAPK
were shown to be relevant, because these could be linked to increases
in the expression of pro-apoptotic proteins Bax and Bak in RF-PRT plate-
lets [65]. In this study inhibition of p38MAPK with SB203580 reversed
most of the pro-apoptotic responses including caspase action. The
same researchers also showed that RF-PRT treatment can be success-
fully postponedwith a beneﬁcial effect on platelet quality in comparison
to PC treated immediately after component preparation [66]. Whether
this is sufﬁciently practical remains to be determined, but the fact that
there is no photosensitizer removal step makes this modiﬁcation
worthwhile investigating.Please cite this article as: Feys HB, et al, Biomolecular Consequences of Plat
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There is consensus that RF-PRT speciﬁcally increases platelet anaero-
bic metabolism rates. In biochemical terms, this observation is not neces-
sarily similar to an acceleration of platelet storage lesion per se as recently
demonstrated by Salunkhe et al [67]. Most studies nonetheless ﬁnd in-
creased lactic acid production rates in RF-PRT treated PC [42, 68-70].
This is relevant, because lactic acid production rate is one of the few in
vitro platelet measures that correlates reasonably well with transfusion
success [71]. Despite the obvious glycolytic shift, depolarization of mito-
chondria in RF-PRT treated platelets is not [69, 72] or just slightly in-
creased [70, 73]. Therefore, other mechanisms must cause the
heightened level of glycolysis in RF-PRT platelets. All studies have focused
onmitochondrial polarization using probes like JC-1 and ﬂow cytometry.
Other more delicate aspects of platelet mitochondrial respiration can be
investigated nowadays using more advanced techniques [34] to fully un-
derstand the metabolic consequence of RF-PRT. For instance, Dahiya et al
demonstrated that changes to miRNA's during platelet storage may indi-
rectly affect respiration by changing the transcription of a subunit of the
F0ATPase complex [74]. Data from the Devine team suggest a link be-
tween changes in mitochondrial respiration, p38MAPK signaling and ap-
optosis of RF-PRT platelets [65, 73]. This deserves further attention
because RF-PRT technology could be used for inactivating whole blood
[58]. The latter is very relevant in endemic regions where the platelet
quality is in balancewith risk for transmission of infectious disease. A bet-
ter insight into the mechanisms of altered platelet metabolism may one
day help to take measures to protect platelets or even red blood cells
from the consequences of RF-PRT in PC and in whole blood, respectively.
In our institute, RF-PRT was not implemented because N10% of prod-
ucts had unacceptable swirling before expiration, including pH b6.4 for
some of these. The Belgian requirement for producing PC that contain
more than 3.0 X 1011 platelets pushed the lower boundaries of platelet
content to levels that were incompatible with the RF-PRT method [75].
The metabolic impact was too large for assured quality of most products
until day 5. It should be noted that our data furthermore indicate that
also for AS-PCT, platelet content combined with primary product type
(apheresis versus buffy coat) can change the rates of storage lesion [76].
A high platelet content in apheresis products is more likely to have in-
creased storage lesion rates than a low content, in the context of AS-PCT.
UV C Light
The UV Cmethod is a one-step illumination with UV C light. The PC is
transferred to a specially designed large transparent container. The large
size increases the total surface area and renders the volume column less
high. Combinedwith constant vigorous agitation, efﬁcient UV C light pen-
etrance is achieved. The energy delivered is 0.2 J/cm2 from both sides of
the bag for about 30 to 60 seconds [4, 9]. The highest intensity of incoming
light is delivered at a peakwavelength of 254 nm, but there is no informa-
tion on additional wavelengths illuminating the PC. A laser is required to
achieve absolutemonochromatic light and this is not part of the Theraﬂex
UVCequipment. Therefore, lower intensity light of other unknownwave-
lengths is delivered to PC during treatment in the illuminator.
The advantage of this technology is the absence of exogenously
added photosensitizers and their photoproducts that are generated dur-
ing excitationwith UV light. The biochemical mechanism of nucleic acid
damage byUV C iswell described [77]. Pyrimidine dimers are generated
which prevent replication of the genetic material and effectively inacti-
vate pathogen proliferation. The method is not in routine use, but a
phase I trial has indicated good tolerance in healthy volunteers receiv-
ing autologous transfusion [78]. A phase III clinical trial is under way
(EUDRACT n° 2015–001035-20).
Similar to the other two PI methods, in vitro platelet concentrate
quality has been studied for UV C as well [4, 79, 80]. In our microﬂuidic
model system for hemostasis, thrombus formation kinetics of UV C
platelets was signiﬁcantly decreased after storage (day 5) comparedelet Pathogen InactivationMethods, Transfus Med Rev (2018), https://
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generates ROS [82], the UV C procedure was repeated in hypoxic condi-
tions but this could not rescue the decreased thrombus formation after
storage. Unlike the other two methods, the impact on thrombus forma-
tion under ﬂow was less obvious immediately after treatment.
What differs from AS-PCT and RF-PRT is that UV C PI induces a con-
formational change in platelet integrin αIIbβ3, reminiscent of receptor
activation [80, 81, 83]. Seminal work from Verhaar et al suggests that
UV C illumination can directly reduce disulﬁde bonds by photolysis
[84]. Disulﬁde bonds are crucial for biomolecular control over integrins,
including αIIbβ3 conformation [85, 86]. Direct photolysis is believed to
trigger dissociation of the intracellular tails of αIIbβ3 thereby releasing
the forces that hold the receptor in a closed conformation. The opened
conformation thus bindsαIIbβ3 ligands like ﬁbrinogen, which is present
in plasma and platelet α-granules. The inﬂuence of UV C on protein di-
sulﬁde bonds may also be related to changes on the proteome level be-
cause Mohr et al showed alterations in the protein disulﬁde isomerase
(PDI) isoform ERp72 [4]. A direct link between integrin activation and
PDI has been shown in genetically modiﬁed mice [87] suggesting that
changes in these enzymes levels can contribute to the observation.
The immediate effect on platelet quality after UV C treatment is less
than for AS-PCT and RF-PRT in our hands. However, storage of UV C
platelets causes increased lactic acid production rates, P-selectin expo-
sure and phosphatidylserine exposure compared to untreated control
[81]. The open conformation of some integrin αIIbβ3 receptors may
cause low but constitutive ﬁbrinogen binding. This in turn may render
(some) UV C treated platelets “primed” for activation increasing con-
sumption of energy and reaching exhaustion faster. Experiments in
the presence of a potent integrin αIIbβ3 inhibitor should conﬁrm or re-
fute this hypothesis.
Conclusion
Recent clinical trials have assessed bleeding in hematology-oncology
patients with thrombocytopenia, both for AS-PCT (EFFIPAP) [10] and
RF-PRT (PREPAReS) [88] compared to their respective untreated con-
trols. The results indicate that non-inferiority of PI treated platelet con-
centrates is questionable, at least for this endpoint and patient
population. These clinical data are accompanied by themultitude of lab-
oratory data that have indicated low to substantial platelet damage fol-
lowing PI in vitro, or at least found changes in platelet function during PC
storage. From the limited basic biochemical studies available we can
conclude that the molecular details behind this damage probably differ
per PI method. This adds to the complexity of the ﬁeld. Additional re-
search to the basic phenomena that lead to platelet damage after PI
should be conducted to explain the observations in the clinic. The indis-
putable advantage of mitigating transfusion transmitted infectious dis-
ease by PI must be compatible with a high quality platelet that
functions as near as possible to an untreated one. This will require a bet-
ter understanding of the platelet's reaction to PImethods and the devel-
opment of creative solutions to counteract these.
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